These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 637461)

  • 1. [Study of a lymphokine acting upon vascular permeability. Initial application in renal pathology].
    Lagrue G; Sobel A; Branellec A; Blanc C
    Ann Med Interne (Paris); 1978 Jan; 129(1):57-60. PubMed ID: 637461
    [No Abstract]   [Full Text] [Related]  

  • 2. A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome.
    Lagrue G; Xheneumont S; Branellec A; Hirbec G; Weil B
    Biomedicine; 1975 Feb; 23(1):37-40. PubMed ID: 1174637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Letter: Lymphokines and nephrotic syndrome.
    Lagrue G; Xheneumont S; Branellec A; Weil B
    Lancet; 1975 Feb; 1(7901):271-2. PubMed ID: 46408
    [No Abstract]   [Full Text] [Related]  

  • 4. Lymphokine 'skin reactive factor' (SRF) and the nephrotic syndrome.
    Lagrue G; Branellec A; Xheneumont S; Weil B
    Bibl Anat; 1975; 13():331-4. PubMed ID: 1231773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vascular permeability factor in the supernatant of lymphocyte cultures in subjects with nephrotic syndrome].
    Lagrue G; Branellec A; Xheneumont S; Hanbec G; Weil B
    J Urol Nephrol (Paris); 1975; 81(4-5):344-8. PubMed ID: 1099228
    [No Abstract]   [Full Text] [Related]  

  • 6. Vascular permeability factor produced by lymphocytes of patients with nephrotic syndrome.
    Sobel A; Heslan JM; Branellec A; Lagrue G
    Adv Nephrol Necker Hosp; 1981; 10():315-32. PubMed ID: 6791474
    [No Abstract]   [Full Text] [Related]  

  • 7. [Factor of capillary permeability in lymphocyte culture supernatant in nephrotic syndromes. Preliminary results].
    Lagrue G; Xhenemont S; Branellec A
    Nouv Presse Med; 1973 Jun; 2(25):1719. PubMed ID: 4718546
    [No Abstract]   [Full Text] [Related]  

  • 8. Physicochemical characterization of a vascular permeability factor produced by con A-stimulated human lymphocytes.
    Sobel AT; Branellec AI; Blanc CJ; Lagrue GA
    J Immunol; 1977 Oct; 119(4):1230-4. PubMed ID: 894032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrotic state as a risk factor for developing posterior reversible encephalopathy syndrome in paediatric patients with nephrotic syndrome.
    Ishikura K; Ikeda M; Hamasaki Y; Hataya H; Nishimura G; Hiramoto R; Honda M
    Nephrol Dial Transplant; 2008 Aug; 23(8):2531-6. PubMed ID: 18258739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular mechanism of edema formation in nephrotic syndrome].
    Deschênes G; Guigonis V; Doucet A
    Arch Pediatr; 2004 Sep; 11(9):1084-94. PubMed ID: 15351000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of soluble immune response suppressor lymphokine in the prediction of steroid responsiveness in idiopathic nephrotic syndrome.
    Cheng IK; Jones BM; Chan PC; Chan MK
    Clin Nephrol; 1989 Oct; 32(4):168-72. PubMed ID: 2805458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-15 and interleukin-12 have an additive effect on the release of vascular permeability factor by peripheral blood mononuclear cells in normals and in patients with nephrotic syndrome.
    Matsumoto K; Kanmatsuse K
    Clin Nephrol; 1999 Jul; 52(1):10-8. PubMed ID: 10442490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Glomerular permeability of plasma-proteins and therapy of nephrotic syndrome].
    Brancaccio D; Locatelli F; Ponticelli C; Imbasciati E
    Minerva Nefrol; 1969; 16(3):223-7. PubMed ID: 5356051
    [No Abstract]   [Full Text] [Related]  

  • 14. Vascular permeability factor and nephrotic syndrome.
    Trompeter RS; Barratt TM; Layward L
    Lancet; 1978 Oct; 2(8095):900. PubMed ID: 81452
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular mechanism of edema formation in nephrotic syndrome: therapeutic implications.
    Doucet A; Favre G; Deschênes G
    Pediatr Nephrol; 2007 Dec; 22(12):1983-90. PubMed ID: 17554565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nephrotic syndrome--a new look at the pathology and pathophysiology.
    Burke BA; Mauer SM; Fish AJ; Michael AF; Vernier RL
    Minn Med; 1975 Jan; 58(1):30-42. PubMed ID: 1088974
    [No Abstract]   [Full Text] [Related]  

  • 17. [New findings on the pathogenesis of nephrotic syndrome (review article)].
    Tesar V; Zima T; Kalousová M
    Sb Lek; 2002; 103(3):379-95. PubMed ID: 12688182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The debatable aspects of the pathogenesis of nephrotic edema].
    Kaiukov IG; Kozlov VV; Kotovoĭ IuO; Degtereva OA; Nikogosian IuA; Kucher AG; Rogachev BV; Ermakov IuA
    Ter Arkh; 1990; 62(11):145-51. PubMed ID: 2094980
    [No Abstract]   [Full Text] [Related]  

  • 19. Vascular permeability increasing factor (VPF) in IgA nephropathy.
    Bakker WW; Beukhof JR; van Luijk WH; van der Hem GK
    Clin Nephrol; 1982 Oct; 18(4):165-7. PubMed ID: 7140031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The vascular permeability factor is a T lymphocyte product.
    Heslan JM; Branellec A; Laurent J; Lagrue G
    Nephron; 1986; 42(2):187-8. PubMed ID: 3484808
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.